2025-04-17T18:27:18Z 2023-12-31 431871840 HRB TAX GROUP INC 1301 MAIN ST STE 101B KANSAS CITY MO 64105 990EZ 2023-01-01 454798068 TESTICULAR CANCER COMMONS TEST 5039978632 10850 NW JACKSON QUARRY RD Hillsboro OR 97124 CRAIG R NICHOLS CEO FOUNDER DIRECTOR 5039978632 2024-04-05 false true Ellis Fowler P00031941 8004725625 2025-04-17 2023 2025-03-06 01:10:19Z X X HTTP://TESTICULARCANCERCOMMONS.ORG/ X X 22569 X 19389 3180 0 22569 5216 18366 60 23642 -1073 9329 8256 9329 8256 9329 8256 9329 8256 SCIENTIFIC CONTRIBUTIONS TO TESTICULAR CANCER KNOWLEDGE BASE IN THE FORM OF SCIENTIFIC COLLABORATIONS, INITIATE AND FACILITATE PROJECTS AND PUBLICATIONS, LEAD OR CO-LEAD SCIENTIFIC PROJECTS FOR PUBLICATION AND PRESENTATION TO PEERS None CRAIG R NICHOLS MD CEO FOUNDER DIRECTOR 0.00 0 BRANDON HAYES LATTIN MD SCIENTIFIC DIRECTOR 0.00 0 CHRISTIAN KOLLMANNSBERGER MD SCIENTIFIC DIRECTOR 0.00 0 DANE NICHOLS MD TREASURER 0.00 0 CHARLES LOPEZ MD SCIENTIFIC DIRECTOR 0.00 0 false false false false false false false false CRAIG R NICHOLS 1210 FARRINGTON DR Knoxville TN 37923 5039978632 false false false false false false false false false false false NONE NONE X OHSU PORTLAND OR PART 1 LINE 1 REVENUE DONNER DIRECTED CONTRIBUTION FROM EARL E AND PHYLLIS G NICHOLS TRUST PART 1 LINE 1 REVENUE CHANGES PRIOR TO PANDEMIC, TESTICULAR CANCER COMMONS (TCC) WAS ABLE TO ACCRUE RAINY DAY FUND THROUGH ACCUMULATION FOR DIRECT COST FROM 2 RESOURCES PART 1 LINE 1 REVENUE CHANGE DR. NICHOLS WAS ELECTED AS TREASURE AND A MEMBER OF THE EXECUTIVE COMMITTEE OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) PART1 LINE 1 REVENUE CHANGE AS PARTICAL COMPENSATION FOR HIS SERVICE, ASCO GAVE ANNUAL GRANTS TO TCC AVERAGING $50K TO $60K ANNUALLY PART1 LINE REVENUE CHANGE TCC ACCURED INDIRECT COST AND PASSED SOME THROUGH TO DR NICHOLS AS MONETARY COMPENSATION FOR THE SIGINIFICANT TIME COMMITMENT AWAY FROM TCC, HIS PRIMARY INSTITUTION PART 1 LINE 1 REVENURE CHANGE FOR SOME YEARS, TCC WAS ABLE TO RUN POSITIVE BALANCE THROUGH THE ASCO. DONATION AND INDIRECT COSTSACCRUAL FROM FEDERAL SCIENTIFIC GRANTS PART 1 LINE 1 REVENUE CHANGE NDEMIC PART 1 LINE 1 REVENUE CHANGE WITH THE PANDEMIC AND SIGNIFICANT DECLINING REVENUE, TCC WAS FORCED TO PIVOT TO AN ADMISTRATIVE ONLY TELEHELTH MODEL OF BUSINESS WHICH FULLY TRANSPIRED BY THE END OF 2022 PART 1 LINE 1 REVENUE CHANGE IN 2021, TESTICULAR CANCER COMMOMS RELOCATED TO KNOXVILLE TN FOR PROXIMITY TO UNIFORMED SERVICE UNIVERSITY AND VANDERBILT UNIVERSITY. CIRCUMSTAXCES CHANGED IN EARLY 2024. NECESITATING A MOVE BACK TO PORTLAND OREGON PART 1 REVENUE CHANGE CONTINUED TCC FULLY INVESTED AND CONTINUES UTILIZING TELETHELTH AND SOCAIL MEDIA CAPACITIES TO ACCOMPLISH THE MISSION OF DISSEMINATION OF KNOWLEDGE FOR TESTICULAR CANCER. THIS IS CULMUNATING IN THE INTERIM AYAYSIS OF THE FEDERALLY SPONSORED NORTH AMERICAN CLINICAL TRIAL OF A NEW BIOMARKER IN TESTICULAR CANCER. TCC AND DR. NICHOLS ARE PRINCIPLALS IN THIS US/CANDIAN EFFORTT PART 1 BEGINING IN 2023 AND LIKELY CONTINUING FOR THE FORESEEABLE FUTURE, TCC WILL OPERATE ON A BUDGET OF ABOUT $20000/YEAR WITH NO COMPENSATION FOR DR.NICHOLS OR OTHER OFFICERS PART 1 REVENUE CHANGE CONTINUE IN KEEPING THE FULL TELEHELTH MODEL, EXPENSE ARE CONFIND IN OFFICE SPACE, COMPUTER, ROUTERS, PRINTERS, SUBSCRIPTIONS, PHONES, ADOBE, OFFICE, QUICKBOOKS, JOURNALS, BUSINESS INTERNET, NETWORK SOFTWARE, SECURITY SOFTWARE, AND SOME TRAVEL TO BRITISH COLUMBIA, WASHINGTON DC AND SEATTLE.